标题: Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells [打印本页] 作者: StephenW 时间: 2010-5-26 13:19 标题: Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells
本帖最后由 风雨不动 于 2012-4-14 16:35 编辑
Viral Hepat. 2010 May 17. [Epub ahead of print]
Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic
cells in patients with chronic hepatitis B.
Akbar SM, Furukawa S, Horiike N, Abe M, Hiasa Y, Onji M.
Department of Medical Sciences, Toshiba General Hospital, Tokyo, Japan.
Abstract
Summary. The immune modulator capacity of antigen-pulsed dendritic cells (DC)
has been documented in patients with cancers and in animal models of chronic
viral infections. Cancer antigen-pulsed DC are now used for treating patients
with cancer. But viral antigen-pulsed DC are not used in chronic
viral-infected patients because safety of antigen-pulsed DC has not been
evaluated in these patients. DC were isolated from human peripheral blood
mononuclear cells by culturing with human-grade granulocyte-macrophage colony
stimulating factor and interleukin-4. Human blood DC were cultured with
hepatitis B surface antigen (HBsAg) for 8 h to prepare HBsAg-pulsed DC. After
immunogenicity assessment of HBsAg-pulsed DC in vitro, five million
HBsAg-pulsed DC were administered intradermally to five patients with chronic
hepatitis B (CHB) 1-3 times. HBsAg-pulsed DC were immunogenic in nature
because they produced significantly higher levels of interleukin-12 and
interferon-gamma compared to unpulsed DC (P < 0.05). Also, HBsAg-pulsed DC
induced proliferation of HBsAg-specific T lymphocytes in vitro. CHB patients
injected with HBsAg-pulsed DC did not exhibit generalized inflammation,
exacerbation of liver damage, abnormal kidney function, or features of
autoimmunity. Administration of HBsAg-pulsed DC induced anti-HBs in two
patients and HBsAg-specific cellular immunity in 1 patient. This is the first
study about preparation of antigen-pulsed DC using human consumable materials
for treating patients with CHB. Because HBsAg-pulsed DC were safe for all
patients with CHB and had immune modulation capacity in some patients, phase I
and phase II clinical trials with antigen-pulsed DC in CHB and other chronic
infections are warranted.
PMID: 20487261 [PubMed - as supplied by publisher]